.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
While many biomarkers exist for head and neck cancers, identifying reliable indicators for HPV-negative OPSCC prognosis remains a critical clinical priority. A groundbreaking study published in BMC Medical Genomics provides a major advancement by validating a specific gene signature that stratifies patient risk more effectively. Specifically, the research focuses on the high-risk HPV-negative subtype, which often carries a worse prognosis compared to HPV-positive cases.
To begin, the research team performed an integrated bioinformatics analysis on transcriptomic data from 418 samples. They identified a 33-gene module primarily linked to extracellular matrix (ECM) organization. Within this module, SPP1 (Secreted Phosphoprotein 1) and PLAU (Plasminogen Activator, Urokinase) emerged as the most significant prognostic drivers. Consequently, these genes appear to play a vital role in tumor cell invasion and microenvironment remodeling.
Furthermore, investigators validated these findings at the protein level using immunohistochemistry (IHC) in an independent cohort of 304 patients. Interestingly, the results showed that the SPP1/PLAU signature successfully stratified patients into high- and low-risk groups. High-risk patients demonstrated significantly shorter overall survival, with a striking hazard ratio of 2.71. Therefore, this protein-level validation confirms the clinical robustness of the signature for routine diagnostic application.
In addition to survival prediction, the study highlighted how these biomarkers reflect the underlying dysregulation of ECM pathways. Consequently, clinicians might utilize this signature to better identify patients who require more intensive surveillance or specific adjuvant therapies. Ultimately, this approach moves oncology closer to personalized medicine for oropharyngeal squamous cell carcinoma.
Because HPV-negative tumors often result from cumulative environmental damage like tobacco use, they exhibit high genomic complexity. As a result, this complexity requires specific molecular signatures, like SPP1/PLAU, to accurately predict clinical outcomes beyond traditional TNM staging.
Indeed, the study validated the signature using standard immunohistochemistry (IHC). Since most pathology departments already utilize IHC for routine diagnostics, integrating SPP1 and PLAU testing into current workflows is highly feasible.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Refer to the latest local and national guidelines for clinical practice.
References
Jin G et al. Discovery and validation of a prognostic SPP1/PLAU signature in HPV-negative oropharyngeal squamous cell carcinoma. BMC Med Genomics. 2026 Jun 16. doi: 10.1186/s12920-026-02400-y. PMID: 42304187.
Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular landscape of head and neck cancer. Nat Rev Cancer. 2011;11(1):9-22. doi: 10.1038/nrc2982.
Johnson DE, Burtness B, Leemans CR, et al. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6(1):92. doi: 10.1038/s41572-020-00224-3.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Researchers have identified a 33-gene signature, centered on SPP1 and PLAU, which significantly predicts survival in HPV-negative oropharyngeal squamous cell carcinoma. Validated via IHC, this signature offers a robust tool for risk stratification in high-risk patients.
4 months ago
Depemokimab offers twice-yearly dosing for severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps, significantly cutting exacerbations and hospital admissions.
3 days back
A novel copper metal-organic framework hydrogel remodels the uterine microenvironment to stimulate robust endometrial regeneration, reduce intrauterine fibrosis, and restore reproductive fertility, offering a groundbreaking strategy for managing refractory endometrial damage and Asherman syndrome.
3 days back
New research reveals that non-ablative radiotherapy suppresses ventricular tachycardia by increasing conduction velocity via NaV1.5 upregulation and action potential prolongation. However, sustained sodium current elevation and depressed calcium handling highlight the need for careful clinical translation.
5 days back
A single-cell transcriptomic atlas reveals how peripheral nerve injuries cause dorsal root ganglion remodeling. By evaluating proximal nerve crush and resection, researchers identify distinct glial and immune programs that resolve neuropathic pain and promote regeneration.
3 days back
A breakthrough study demonstrates that fullerol-primed extracellular vesicles generated in a 3D SECCS bioreactor attenuate ferroptosis and restore myogenic regeneration in diabetes via the FOXO3 pathway, offering a cell-free therapeutic strategy for diabetic musculoskeletal degeneration.
3 days back
